Although small molecule or peptide-based inhibitors against individual NSPs have been extensively explored in the past 50 years, efforts of the pharmaceutical industry so far have created little impact in the clinic, except for AAT augmentation therapy in patients with emphysema and congenital AATD (191). The gene discussed is SERPINA1; the disease is pulmonary emphysema.